Key Highlights
- Shares of VolitionRx (VNRX) skyrocketed over 70% during pre-market hours on Wednesday
- The biotech firm achieved over 99% purity in isolating circulating tumor DNA (ctDNA) from patient blood
- Their proprietary Capture-Seq™ technology combines physical sample enrichment with advanced computational analysis
- Clinical testing demonstrated perfect cancer detection: 49/49 cases identified in initial blinded cohort and 13/14 in follow-up group
- VolitionRx identified a potential market opportunity worth approximately $36 billion and is pursuing licensing partnerships
Shares of VNRX exploded more than 70% higher in Wednesday’s pre-market session following VolitionRx’s announcement of what the company characterizes as a transformative advancement in liquid biopsy diagnostics.
The biotech company reported it achieved the successful extraction of circulating tumor-derived DNA (ctDNA) from patient blood at purity levels surpassing 99%. This essentially means the process eliminates virtually all non-cancerous genetic material, isolating an exceptionally clean tumor DNA signature.
Liquid biopsy technology has historically faced a fundamental obstacle: the vast majority of free-floating DNA in human bloodstream originates from normal, healthy cells rather than malignant ones. Extracting a reliable cancer signal from this overwhelming background noise has presented enormous challenges. VolitionRx claims its innovative approach has overcome this barrier.
The company’s Capture-Seq™ methodology employs a dual-phase approach. Initially, the technology physically concentrates the target material. Subsequently, sophisticated bioinformatics algorithms eliminate residual interference. According to VolitionRx, this process yields a dataset with tumor DNA purity exceeding 99%.
Jake Micallef, the company’s Chief Scientific Officer, characterized the achievement as unprecedented globally. He explained that CTCF-bound DNA — the particular genetic marker their system isolates — is virtually undetectable in healthy individuals’ plasma but represents almost exclusively cancer-derived material in patients with malignancies.
“Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long-term goal of liquid biopsy,” Micallef said in the company’s release.
Clinical Performance in Blinded Testing
VolitionRx disclosed findings from two separate blinded cohort evaluations. The initial study achieved flawless performance, identifying all 49 cancer cases without exception. The secondary cohort yielded detection of 13 cancers among 14 total cases.
These figures represent preliminary-stage data, with relatively limited sample sizes. More extensive clinical validation will be essential before any potential commercial deployment. Additionally, the methodology captures only a specific fraction of ctDNA, suggesting some tumor-derived fragments may potentially evade detection.
The company has submitted a revised manuscript to Research Square, an online preprint repository. The research has not yet completed peer review, which represents standard protocol before scientific findings gain broader acceptance within the medical research community.
Commercial Opportunity and Strategic Positioning
VolitionRx referenced a cumulative addressable market valued at roughly $36 billion, encompassing both multi-cancer early detection (MCED) applications and minimal residual disease (MRD) surveillance.
The biotech firm indicated it is currently engaged in ongoing negotiations with prospective diagnostic industry licensing partners. No formal agreements have been disclosed to date.
VNRX shares were positioned to close above their 100-day moving average for the first time since October 8, 2025, assuming pre-market momentum sustained through the regular trading session.
According to the company, the revised preprint manuscript should appear on Research Square in the near term.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
